IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER and E. NEUFELD. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. Hoboken: Wiley, 2017, vol. 15, No 12, p. 2461-2465. ISSN 1538-7933. Available from: https://dx.doi.org/10.1111/jth.13867.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH
Authors IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER and E. NEUFELD.
Edition Journal of Thrombosis and Haemostasis, Hoboken, Wiley, 2017, 1538-7933.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.899
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/jth.13867
UT WoS 000417211100022
Keywords in English hemophilia A; hemophilia B
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 13:09.
Abstract
The ISTH SSC on Factor VIII/IX has previously issued guidelines for studies assessing the pharmacokinetics (PK) of factor concentrates [1, 2]. It suggested drawing 10 or 11 blood samples over a period of 32-48 h or 50-72 h, after infusing 25-50 IU kg-1 or 50-75 IU kg-1, respectively, for FVIII or FIX, in cohorts of 12-15 patients with a crossover design. Such PK studies are not ideal for tailoring the treatment of individual patients, mostly because of the requirement for several blood samples. Owing to broad interindividual variation, the individual disposition of FVIII and FIX cannot be predicted from morphometric characteristics and average PK parameters, but requires empirical assessment in each individual [3-6]. Previous guidance of this ISTH SSC described the PK methodology for the prediction of individual trough levels of FVIII [7]. The present communication, building on recent advances in the population pharmacokinetics (PopPK) of FVIII and FIX [8], adds to the former documents.
PrintDisplayed: 12/5/2024 22:34